Page 121 - MemoriaEHD-Eng

www.ciberehd.org

• r C, g J, a iK, g i, a s, t M. Rebleeding prophylaxis
Most relevant ipoLLeNesCàrauJorauperaugustiNeJeDor
improves outcomes in patients with hepatocellular carcinoma. A multicenter case-
scientific control study.Hepatology. 2013 Dec;58(6):2079-88.

articles
• arMeNgoL C, BartoLí r, saNJurJo L, serra i, aMézaga N, saLa M. Role of scavenger
receptors in the pathophysiology of chronic liver diseases.Crit Rev Immunol.

2013;33(1):57-96.

• saLuDes v, BasCuñaNa e, JorDaNa-LLuCh e, CasaNovas s, arDèvoL M, soLer e. Relevance of
baseline viral genetic heterogeneity and host factors for treatment outcome predic-

tion in hepatitis C virus 1b-infected patients.PLoS One. 2013;8(8):e72600.

• saLuDes v, goNzáLez-CaNDeLas F, pLaNas r, soLà r, ausiNa v, Martró e. Evolutionary dy-
namics of the E1-E2 viral populations during combination therapy in non-responder

patients chronically infected with hepatitis C virus subtype 1b.Infect Genet Evol.
2013 Jan;13:1-10.

• u JJ, D M, B J, p r, s r, D o Ja. Safety and efficacy of
rQuiJoiagooaDasLaNasoLáeLLMo
treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C

genotype 4.Ann Hepatol. 2013 Jan-Feb;12(1):30-5.

Highlights
The group has developed its activity in the scientific research program on portal
hypertension and mechanisms of transition to cirrhosis, viral hepatitis, liver can-

cer and liver immunology. In 2013, the group has led five competitive projects
from the National Health Institute CarlosIII , FIS (PI 09/ 00751 , PI10/08082 ,

PI11/00187 , PI10/01565 and PI10/1656 ) and participated in another project(

PI10/00132 ) . We also led a regional project (2009SGR00738, Generalitat de
Catalunya). Also, during 2013 we have obtained 4 new projects (PI13/01906,

PI13/02340, PI13/02217, and one “Marato de TV3”). As a result of scientific activ-

ity, the group has generated a total number of 11 international publications and
one book chapter (total impact factor of 36.57). Likewise, there have been seven

communications to international congresses and 16 national conferences, as well
as invitations to 57 national and international conferences. Three doctoral theses

supervised by members of the group were presented during 2013. The group has

organized and coordinated, in conjunction with other Ciber groups, clinical courses
in the field of gastroenterology and hepatology. The number of active clinical trials

this year has been 14, most of them in collaboration with other Ciber, and inter-

national groups. Moreover, several group members are part of the editorial board
of several journals, also a member of the group coordinates the Spanish Study

Group of childhood liver tumors SEOHP. Finally, the total public funding during
2013 (FIS, SGR) amounted to € 122,329 and private funds (clinical trials, agree-

ments, grants) have been raised € 219,000.

13
20
T
OR
P
RE
L
A
NU
N
A
D /
H
E
ER
IB
C

121